Biologics Overcapacity Concern Rears its Head.

Reports on the investments made by chemical companies in building biologics capacity and acquiring biomanufacturing firms. Factors that may lead to short-term overcapacity in the biologics sector; Problems facing the biologics intermediates sector; Questions raised about the level of biologics outsourcing by the pharmaceutical industry.